G
Giuseppe Giaccone
Researcher at Cornell University
Publications - 168
Citations - 13062
Giuseppe Giaccone is an academic researcher from Cornell University. The author has contributed to research in topics: Lung cancer & Thymic carcinoma. The author has an hindex of 40, co-authored 168 publications receiving 9472 citations. Previous affiliations of Giuseppe Giaccone include Harvard University & University of Washington.
Papers
More filters
Journal ArticleDOI
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
Peter Goldstraw,Kari Chansky,John Crowley,Ramón Rami-Porta,Hisao Asamura,Wilfried Ernst Erich Eberhardt,Andrew G. Nicholson,Patti A. Groome,Alan Mitchell,Vanessa Bolejack,David Ball,David G. Beer,Ricardo Beyruti,Frank C. Detterbeck,Wilfried Eberhardt,John G. Edwards,Françoise Galateau-Salle,Dorothy Giroux,Fergus V. Gleeson,James Huang,Catherine Kennedy,Jhingook Kim,Young Tae Kim,Laura Kingsbury,Haruhiko Kondo,Mark Krasnik,Kaoru Kubota,Antoon Lerut,Gustavo Lyons,Mirella Marino,Edith M. Marom,Jan P. van Meerbeeck,Takashi Nakano,Anna K. Nowak,Michael D Peake,Thomas W. Rice,Kenneth E. Rosenzweig,Enrico Ruffini,Valerie W. Rusch,Nagahiro Saijo,Paul Van Schil,Jean-Paul Sculier,Lynn Shemanski,Kelly G. Stratton,Kenji Suzuki,Yuji Tachimori,Charles F. Thomas,William D. Travis,Ming-Sound Tsao,Andrew T. Turrisi,Johan Vansteenkiste,Hirokazu Watanabe,Yi-Long Wu,Paul Baas,Jeremy J. Erasmus,Seiki Hasegawa,Kouki Inai,Kemp H. Kernstine,Hedy L. Kindler,Lee M. Krug,Kristiaan Nackaerts,Harvey I. Pass,David C. Rice,Conrad Falkson,Pier Luigi Filosso,Giuseppe Giaccone,Kazuya Kondo,Marco Lucchi,Meinoshin Okumura,Eugene H. Blackstone,F. Abad Cavaco,E. Ansótegui Barrera,J. Abal Arca,I. Parente Lamelas,A. Arnau Obrer,R. Guijarro Jorge,D. Ball,G.K. Bascom,A. I. Blanco Orozco,M. A. González Castro,M.G. Blum,D. Chimondeguy,V. Cvijanovic,S. Defranchi,B. de Olaiz Navarro,I. Escobar Campuzano,I. Macía Vidueira,E. Fernández Araujo,F. Andreo García,Kwun M. Fong,G. Francisco Corral,S. Cerezo González,J. Freixinet Gilart,L. García Arangüena,S. García Barajas,P. Girard,Tuncay Göksel,M. T. González Budiño,G. González Casaurrán,J. A. Gullón Blanco,J. Hernández Hernández,H. Hernández Rodríguez,J. Herrero Collantes,M. Iglesias Heras,J. M. Izquierdo Elena,Erik Jakobsen,S. Kostas,P. León Atance,A. Núñez Ares,M. Liao,M. Losanovscky,G. Lyons,R. Magaroles,L. De Esteban Júlvez,M. Mariñán Gorospe,Brian C. McCaughan,Catherine J. Kennedy,R. Melchor Íñiguez,L. Miravet Sorribes,S. Naranjo Gozalo,C. Álvarez de Arriba,M. Núñez Delgado,J. Padilla Alarcón,J. C. Peñalver Cuesta,Jongsun Park,H. Pass,M. J. Pavón Fernández,Mara Rosenberg,Enrico Ruffini,V. Rusch,J. Sánchez de Cos Escuín,A. Saura Vinuesa,M. Serra Mitjans,Trond Eirik Strand,Dragan Subotic,S.G. Swisher,Ricardo Mingarini Terra,Charles R. Thomas,Kurt G. Tournoy,P. Van Schil,M. Velasquez,Y.L. Wu,K. Yokoi +142 more
TL;DR: The methods used to evaluate the resultant Stage groupings and the proposals put forward for the 8th edition of the TNM Classification for lung cancer due to be published late 2016 are described.
Journal ArticleDOI
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris,Bruce E. Johnson,Lynne D. Berry,David J. Kwiatkowski,A. John Iafrate,Ignacio I. Wistuba,Marileila Varella-Garcia,Wilbur A. Franklin,Samuel J. Aronson,Pei Fang Su,Yu Shyr,D. Ross Camidge,Lecia V. Sequist,Bonnie S. Glisson,Fadlo R. Khuri,Edward B. Garon,William Pao,Charles M. Rudin,Joan H. Schiller,Eric B. Haura,Mark A. Socinski,Keisuke Shirai,Heidi Chen,Giuseppe Giaccone,Giuseppe Giaccone,Marc Ladanyi,Kelly Kugler,John D. Minna,Paul A. Bunn +28 more
TL;DR: The Lung Cancer Mutation Consortium was formed to perform multiplexed assays testing adenocarcinomas of the lung for drivers in 10 genes to enable clinicians to select targeted treatments and enroll patients into clinical trials.
Journal ArticleDOI
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Roy S. Herbst,Giuseppe Giaccone,Filippo de Marinis,Niels Reinmuth,Alain Vergnenegre,Carlos H. Barrios,Masahiro Morise,Enriqueta Felip,Z. Andric,Sarayut Lucien Geater,Mustafa Ozguroglu,Wei Zou,Alan Sandler,Ida Enquist,Kimberly Komatsubara,Yu Deng,Hiroshi Kuriki,X. Wen,Mark McCleland,Simonetta Mocci,Jacek Jassem,David R. Spigel +21 more
TL;DR: Atezolizumab treatment resulted in significantly longer overall survival than platinum-based chemotherapy among patients with NSCLC with high PD-L1 expression, regardless of histologic type.
Journal ArticleDOI
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Gregory A. Masters,Sarah Temin,Christopher G. Azzoli,Giuseppe Giaccone,Sherman Baker,Julie R. Brahmer,Peter M. Ellis,Ajeet Gajra,Nancy Rackear,Joan H. Schiller,Thomas J. Smith,John R. Strawn,David Trent,David H. Johnson +13 more
TL;DR: This guideline update reflects changes in evidence since the previous guideline and recommends combination cytotoxic chemotherapy is recommended, guided by histology, with early concurrent palliative care.
Journal ArticleDOI
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
Marina Chiara Garassino,Olga Martelli,Massimo Broggini,Gabriella Farina,Silvio Veronese,Eliana Rulli,F. Bianchi,Anna Cecilia Bettini,Flavia Longo,Luca Moscetti,M. Tomirotti,Mirko Marabese,Monica Ganzinelli,Calogero Lauricella,Roberto Labianca,Irene Floriani,Giuseppe Giaccone,Valter Torri,A. Scanni,Silvia Marsoni +19 more
TL;DR: Chemotherapy is more effective than erlotinib for second-line treatment for previously treated patients with NSCLC who have wild-type EGFR tumours and progression-free survival was significantly better with docetaxel than with erlot inib.